Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Aytu BioPharma Stock Performance
Shares of AYTU Stock remained flat at $0.28 during mid-day trading on Thursday. 1,011,133 shares of the stock were exchanged, compared to its average volume of 839,076. Aytu BioPharma has a 12-month low of $0.26 and a 12-month high of $3.89. The firm's 50 day moving average price is $0.52 and its 200 day moving average price is $0.79. The company has a quick ratio of 0.80, a current ratio of 0.97 and a debt-to-equity ratio of 0.30. The stock has a market cap of $10.86 million, a price-to-earnings ratio of -0.07 and a beta of -0.42.
Aytu BioPharma (NASDAQ:AYTU - Get Rating) last issued its earnings results on Monday, May 16th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.14. Aytu BioPharma had a negative net margin of 120.24% and a negative return on equity of 41.97%. The company had revenue of $24.20 million during the quarter, compared to the consensus estimate of $24.20 million. As a group, equities analysts expect that Aytu BioPharma will post -1.05 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several research firms have weighed in on AYTU. Cantor Fitzgerald cut their price objective on Aytu BioPharma from $11.00 to $5.00 in a research report on Tuesday, May 17th. HC Wainwright decreased their price objective on shares of Aytu BioPharma from $11.00 to $6.00 and set a "buy" rating for the company in a report on Thursday, July 21st.